Zentalis Pharmaceuticals (ZNTL) Stock Forecast & Price Target

ZNTL Forecast - Frequently Asked Questions

What is Zentalis Pharmaceuticals' forecast for 2024?

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Zentalis Pharmaceuticals is $11.33, with a high forecast of $25.00 and a low forecast of $4.00.

Should I buy or sell Zentalis Pharmaceuticals stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zentalis Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ZNTL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZNTL, but not buy additional shares or sell existing shares.

Does Zentalis Pharmaceuticals's stock price have much upside?

According to analysts, Zentalis Pharmaceuticals's stock has a predicted upside of 93.77% based on their 12-month stock forecasts.

Has Zentalis Pharmaceuticals been downgraded by Wall Street analysts recently?

Over the previous 90 days, Zentalis Pharmaceuticals's stock had 3 downgrades by analysts.

What analysts cover Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals has been rated by research analysts at HC Wainwright, Jefferies Financial Group, Morgan Stanley, Oppenheimer, Stifel Nicolaus, UBS Group, Wedbush, and Wells Fargo & Company in the past 90 days.

Do Wall Street analysts like Zentalis Pharmaceuticals more than its competitors?

Analysts like Zentalis Pharmaceuticals less than other "medical" companies. The consensus rating for Zentalis Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZNTL compares to other companies.